Format

Send to

Choose Destination
Nat Biotechnol. 2005 Sep;23(9):1073-8.

Monoclonal antibody successes in the clinic.

Author information

1
Tufts University Center for the Study of Drug Development (CSDD), 192 South Street, Suite 550, Boston, Massachusetts 02111, USA. janice.reichert@tufts.edu

Abstract

Most monoclonal antibodies in clinical trials are owned by small biotech companies. But with blockbuster-sized revenues and approval rates higher than those for small-molecule drugs, that all may be set to change.

PMID:
16151394
DOI:
10.1038/nbt0905-1073
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center